Mead Johnson to operate independently from Bristol-Myers
Bristol-Myers Squibb is divesting Mead Johnson Nutrition to concentrate on biopharmaceuticals. The deal allows Bristol-Myers' shareholders to "exchange some, none or all of their shares of Bristol-Myers Squibb common stock for shares of Mead Johnson common stock," the company said.
Wall Street Journal, The
| 11/15
This story published in FMI Pharmacy dailyLead on 11/16/2009
Get stories like these delivered daily for FREE:
|
FMI Pharmacy dailyLead
Designed specifically for pharmacy professionals, FMI Pharmacy dailyLead is a FREE, daily e-mail newsletter. It provides the latest news in the pharmacy arena. Learn more |
|